A cure that markets itself.And the clinical infrastructure to deliver it.
An application-only acne research cohort for serious practitioners. Two patient channels — your own clients and BMH-assigned referrals. Prescription-anchored topical protocol, gut-microbiome pathway for systemic cases, and a clinical operating system that resolves what most practices only manage.
Acne is the most under-served, highest-referral presentation in your practice.
Most practitioners — even excellent ones — do not have a credible answer for acne. Conventional dermatology trades efficacy for barrier damage. Functional approaches trade clarity for endless supplement stacks. Patients ask anyway. They are asking right now.
Cleared patients refer like nothing else does.
Acne resolution is visible in a way no other clinical outcome is. A cleared patient tells three to five people in their immediate circle who have similar issues. Conservative referral compounding alone produces six to ten new enrollments per ten cleared patients — without acquisition spend.
Cleared patients become your highest-LTV clients.
A patient whose face you fixed will let you run their hormones, their gut, their longevity panels, their peptides. The conversion rate from cleared acne to one additional service line is meaningfully higher than for any transactional patient relationship in functional medicine.
Resolution, not management.
Treated correctly at the gut microbiome, acne does not recur. This is not a maintenance subscription dressed up as a program. It is a definitive intervention with publishable outcomes — and a research cohort designed to prove it.
You have been told acne is chronic.
It is not.
A turnkey acne offering, deployable from day one.
A 12-week, two-pathway protocol anchored in prescription-grade stabilized hypochlorous acid (EO-100), supported by a choreographed sequence of clinical-grade topical activators, with a gut-microbiome repair pathway for systemic cases.
For cutaneous-driven cases.
Full topical clarity system: EO-100 prescription anchor, plus the Rə'jōōv / Rə'act / Rə'stôr activator sequence. Bi-weekly automated tracking. Acceptance interview and completion consultation handled by the BMH clinical team.
For systemic involvement.
Everything in Protocol 01, layered over the Seed · Net · Clear gut-microbiome repair sequence. Liposomal glutathione, binders, mitophagy support. Phase-transition coordination throughout the 12 weeks.
EO-100 prescription is issued under a Program Prescriber on the BMH supervising team — or, where the referring practitioner holds prescribing authority, under their own license. Either path delivers the same protocol.
Patients you bring. Patients we send.
Both channels feed the same 200-patient research cohort. Both produce the same revenue layers for your practice. The difference is where the patient came from — and which channel is open to you depends on the tier you enter at.
Your own clients.
Bring patients from your existing practice into the cohort. They stay your client throughout. You earn margin on the topical kit and the supplementation line. The protocol clears them. They refer their friends — to you.
BMH-assigned patients.
Patients who apply through our patient-facing acne clarity page are routed to membership-tier practitioners on the directory. Patient flow into your practice — without acquisition spend, geographically matched, clinically pre-qualified.
Three layers of revenue. One compounding engine.
Acne treated correctly does not generate recurring product revenue — patients clear and stay clear. The compelling math sits elsewhere: in the patients those cleared patients send you, and in the lifetime value of relationships built on a visible win.
Acquisition margin.
50% wholesale margin on the topical kit. 30% margin on Protocol 02 supplementation through Fullscript. Per-patient economics are reviewed during the application interview, where bundled program pricing is unwound transparently.
Referral compounding.
A cleared acne patient refers three to five people in their immediate circle. At a 20–25% conversion rate, ten cleared patients seeds another six to ten enrollments over the following six to twelve months — and that cohort seeds the next. By month 18, the acne program is the lowest-CAC patient channel in your practice.
Patient lifetime value.
Cleared patients convert to other service lines at materially higher rates than transactional patients. Conservative assumption: 50% of retained cohort patients convert to one additional service at $1,500–2,500 per year. The acne program becomes the front door to the rest of your practice.
Cohort participation, at the depth your practice requires.
Every level includes the monthly cohort meeting with Dr. Lily Woods, PhD. Membership tiers add the Six Pathway clinical infrastructure that extends the methodology across every other condition you treat. Founding-cohort pricing is locked through 2027.
Practitioner
Cohort Practitioner is a free, application-only entry tier. It exists to let serious practitioners experience the methodology and the cohort meeting before committing to membership. Soft-capped at three active patients to keep the tier honest about what it is — and what it is not.
Two decades of precision longevity, applied to acne.
Dr. Lily Woods, PhD is the protocol designer behind Body MAX Harmonics. Her work sits at the intersection of precision longevity, regenerative health, and advanced diagnostic testing — with depth in the gut-microbiome biology that drives systemic acne presentations.
The acne research cohort is the first published outcomes study from the BMH platform. It exists to prove what the methodology can do when applied to a single, visible, high-impact presentation — and to bring that proof to the practitioners running it in their own practices.
Dr. Woods runs the monthly cohort meeting personally. Every cohort patient case is reviewable. Every protocol decision is teachable. Every cleared patient is data.
Who this cohort is built for.
Are you a licensed prescriber?
If you hold prescribing authority and are interested in serving as a prescribing clinician inside the cohort itself — issuing EO-100 prescriptions for cohort patients matched to your state licensure — apply through the Program Prescriber pathway. Compensation is structured into the program. Geographic match is handled at intake. The role is separate from practitioner tier participation, and a single prescriber may hold both.
What approved practitioners ask before applying.
This is not a purchase. It is an admission.
Enrollment in the founding cohort is limited and reviewed on a rolling basis. Every applicant is read by Dr. Woods personally. Where there is alignment, the next step is a conversation. Where there is not, we will tell you so directly.